MARKET WIREStock Titan • 1d ago
A drug being tested for Ebola showed no harmful effects in a young-mouse safety studyStock Titan report covering NanoViricides Inc. (NNVC) market action, institutional positioning, and fundamental catalysts.
Why NNVC Stock advanced +1.50% Today — RQD Quant Desk Flash
$1.35 +1.50% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.35
NanoViricides Inc. (NNVC) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $34.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NNVC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NNVC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, NanoViricides Inc. (NYSE: NNVC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.35 (+1.50% 1D, market cap $34.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NNVC ranks #542 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NNVC compare to LITS and ALDX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NNVC carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LITS (Lite Strategy Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -18.9%, cap $34.1M) and ALDX (Aldeyra Therapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $33.8M). Among the 5-stock peer group, NNVC leads on earnings multiple (N/A) while LITS leads on capital efficiency (-18.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NNVC?
▼
Per NNVC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001379006), NanoViricides Inc. generated $26.9M in revenue (+12.6% YoY), -$9.5M in net income, and -$8.5M in free cash flow against $12.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.35 (+0.08%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NNVC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY NNVC SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)
FRED Regime × Technicals: 36% of 52W Range • RSI-14 at 47.3 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.32+12.1% Next Q
29
Q2 (-2Q)Grade E$1.48-1.4% Next Q
32
Q3 (-1Q)Grade E$1.46-7.5% Next Q
34
CurrentGrade D-$1.35-8.1% Hist 90D α
37
Trajectory: E (29) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NNVC Turnaround Squeeze
While NNVC currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.32) and Max Pain ($1.42) forces dealer call-delta covering toward $2.34.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NNVC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NNVC Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NNVC Stock advanced +1.50% Today — RQD Quant Desk Flash
NanoViricides Inc. (NNVC) advanced +1.50% to $1.35, trading at 36% of its 52-week range ($0.85 – $2.23). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 36% of its 52-week range ($0.85 – $2.23) with RSI-14 at 47.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.35 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live NNVC Headlines & Catalysts
MARKET WIREYahoo Finance • 1d ago
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical TrialsYahoo Finance report covering NanoViricides Inc. (NNVC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREscanx.trade • 1d ago
NanoViricides files prospectus for $2.375M common stock offeringscanx.trade report covering NanoViricides Inc. (NNVC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 LivesYahoo Finance report covering NanoViricides Inc. (NNVC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 2d ago
As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricidesYahoo Finance report covering NanoViricides Inc. (NNVC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 2d ago
IRulya Therapeutics (IRLA) Stock Price, News & AnalysisStock Titan report covering NanoViricides Inc. (NNVC) market action, institutional positioning, and fundamental catalysts.
RISK WATCHcitybuzz - • 2d ago
NanoViricides Reports Positive Juvenile Safety Data for NV-387, But Going Concern Risk Persistscitybuzz - report covering NanoViricides Inc. (NNVC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREcitybuzz - • 2d ago
NanoViricides Advances Oral Ebola Treatment Trial as DRC Outbreak Growscitybuzz - report covering NanoViricides Inc. (NNVC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 7d ago
'Congo Ebola Cases Top 10,000 as Violence Hits Health Workers' - Bloomberghttps://www.bloomberg.com/news/articles/2026-10-27/congo-ebola-cases-top-10-000-as-violence-hits-health-workers
MARKET WIREBenzinga • 11d ago
'Africa at risk of continent-wide Ebola crisis, health chief warns' - Semaforhttps://www.semafor.com/article/10/23/2026/ebola-threat-was-underestimated-africa-cdc-chief-says
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NNVC)
- ✓Walkthrough of NNVC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NNVC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.00%▼ DESCENDING CHANNEL
2026-11-03O $1.43H $1.43L $1.33C $1.35VOL 224.3K
RES: $1.73SUP: $0.88SMA50: $1.32SMA200: $1.29
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NNVC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +12.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on NNVC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NNVC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NNVC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NNVC)
Health Care Rank #542 of 1015
⚔️ LITS vs NNVC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NNVC vs. LITS, ALDX, EDSA, GRDX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, NanoViricides Inc. (NNVC) ranks #542 by composite RQD confidence (37/100, grade D-) and #785 by equity capitalization ($34.0M). Within this direct 5-issuer industry benchmark cohort, NNVC leads on earnings valuation at N/A trailing P/E, while LITS leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. LITS currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with NNVC at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NNVC
ACTIVE
NanoViricides Inc. | D- | 37/100 | — | — | -35.0% | +1.50% | $34.0M | Benchmark Subject |
| LITS Lite Strategy Inc. | D- | 43/100 | — | — | -18.9% | -13.60% | $34.1M | /lits-vs-nnvc → |
| ALDX Aldeyra Therapeutics Inc. | D- | 39/100 | — | — | -35.0% | +4.09% | $33.8M | /aldx-vs-nnvc → |
| EDSA Edesa Biotech Inc. | E | 29/100 | — | — | -35.0% | -5.06% | $34.7M | /edsa-vs-nnvc → |
| GRDX GridAI Technologies Corp. | D- | 39/100 | — | -30.0% | -20.0% | -3.43% | $35.4M | /grdx-vs-nnvc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001379006 ↗In its most recent audited fiscal period (FY2025, filed 2025-06-30), NanoViricides Inc. (NNVC) reported GAAP revenue of $26.9M (+12.6% vs. FY2024 revenue of $23.8M , and +7.2% cumulative change since FY2023) , GAAP net income of -$9.5M, operating cash flow of -$8.5M, and free cash flow of -$8.5M (-31.9% YoY). On the balance sheet, NNVC closed FY2025 with $12.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $26.9M | -$9.5M | -$8.5M | -$8.5M | $12.3M | — |
| FY2024 (FY) | 2024-06-30 | $23.8M | -$8.3M | -$6.3M | -$6.5M | $11.6M | — |
| FY2023 (FY) | 2023-06-30 | $25.0M | -$8.6M | -$5.7M | -$5.7M | — | — |
3. NNVC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NNVC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, NanoViricides Inc. (NYSE: NNVC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.35 (+1.50% 1D, market cap $34.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NNVC ranks #542 in composite RQD confidence.
How does NNVC compare to LITS and ALDX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NNVC carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LITS (Lite Strategy Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -18.9%, cap $34.1M) and ALDX (Aldeyra Therapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $33.8M). Among the 5-stock peer group, NNVC leads on earnings multiple (N/A) while LITS leads on capital efficiency (-18.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NNVC?
Per NNVC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001379006), NanoViricides Inc. generated $26.9M in revenue (+12.6% YoY), -$9.5M in net income, and -$8.5M in free cash flow against $12.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NNVC trading relative to its 50-day, 200-day, and 52-week technical levels?
NNVC last traded at $1.35 (+1.50% on volume of 77,749 shares), positioning the stock +2.27% above its 50-day simple moving average ($1.32) and +4.65% above its 200-day simple moving average ($1.29). Across its 52-week range of $0.85 to $2.23, NNVC sits at the 36.2% percentile with a 14-day RSI of 47.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.18 to $1.52).
ROARABLE RATING BRIEF • RQD 37/100 (D-)
✓ SEC XBRL & RQD VERIFIED
NNVC — NanoViricides Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30
1. Roarable Rating Brief: What This Means to a Prospective Investor
NanoViricides Inc. (NNVC) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.35 (+1.50% 1D, market capitalization $34.0M).
- Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -23.37%.
- Whale 13F & Options Flow (8/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
. Is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. — regarding specific products sold, customer base, or revenue model; the financials report — revenue in each reported period. The source notes a $0.0B market capitalization in the profile, which conflicts with the $36.5M figure in market data; this should be treated as an unresolved discrepancy.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), NanoViricides Inc. (NNVC) reported $26.9M in annual revenue (up from $23.8M in FY2024, +12.6% YoY) and -$9.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($25.0M revenue, -$8.6M net income) through FY2025, NNVC scaled operating cash flow to -$8.5M and free cash flow to -$8.5M, backed by $12.3M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -23.37% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $0.85 – $2.23 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), NNVC carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can NNVC sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $26.9M and free cash flow of -$8.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is NNVC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
NNVC Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for NanoViricides Inc. (NNVC) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Stock Titan • 1d ago
A drug being tested for Ebola showed no harmful effects in a young-mouse safety study Stock Titan report covering NanoViricides Inc. (NNVC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials Yahoo Finance report covering NanoViricides Inc. (NNVC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE scanx.trade • 1d ago
NanoViricides files prospectus for $2.375M common stock offering scanx.trade report covering NanoViricides Inc. (NNVC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives Yahoo Finance report covering NanoViricides Inc. (NNVC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 2d ago
As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides Yahoo Finance report covering NanoViricides Inc. (NNVC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 2d ago
IRulya Therapeutics (IRLA) Stock Price, News & Analysis Stock Titan report covering NanoViricides Inc. (NNVC) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH citybuzz - • 2d ago
NanoViricides Reports Positive Juvenile Safety Data for NV-387, But Going Concern Risk Persists citybuzz - report covering NanoViricides Inc. (NNVC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE citybuzz - • 2d ago
NanoViricides Advances Oral Ebola Treatment Trial as DRC Outbreak Grows citybuzz - report covering NanoViricides Inc. (NNVC) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
NNVC Bull vs. Bear Conversation Board — What's Your Call at $1.35?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NNVC 🐻 33% BEARISH CONVICTION
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH
🎯 Target: $1.74 (+30.8%)
📌 Pinned Debate Recent safety data on NV-387 in juvenile mice and an ongoing Ebola Phase II trial could support a pediatric clinical pathway.
Don't sleep on NNVC's setup in Health Care. Recent safety data on NV-387 in juvenile mice and an ongoing Ebola Phase II trial could support a pediatric clinical pathway.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (37/100) backs up the fundamental quality.
SectorRotator 🐂 BULL
@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH
🎯 Target: $1.08 (-18.8%)
Spot @ $1.33 Negative ROIC of -35%, negative free cash flow yield of -23.37%, and a $2.375M stock offering point to continued cash burn and dilution
Here is the bear case nobody on the bull side wants to address on NNVC: Negative ROIC of -35%, negative free cash flow yield of -23.37%, and a $2.375M stock offering point to continued cash burn and dilution risk.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.